Opendata, web and dolomites

TRAIN-OLD SIGNED

Trained immunity: improving the next generation of vaccines for the older generation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TRAIN-OLD" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 2˙262˙500.00
2    ELLINIKO INSTITUTO MELETIS TIS SIPSIS EL (ATHENS) participant 237˙500.00

Map

 Project objective

The host defense, especially the adaptive immunity, is defective in the elderly, with a dramatic drop for the efficacy of vaccination with old age. Interestingly however, the innate immunity of older individuals is relatively intact, and we recently described that epigenetic and functional reprogramming of innate immune cells by certain vaccines and mild infections, termed ‘trained immunity’, induces potent heterologous protection against infections. I propose that induction of trained immunity is an important novel approach to improved vaccination in the elderly. Induction of trained immunity is regulated by the interaction between the host genome, microbiome, and the epigenetic and metabolic programs of specific populations of myeloid cells, and we need to understand how these factors are impacted by age and gender of the host. By understanding the factors that impact the response to BCG (Bacille Calmette-Guerin), the prototype vaccine that induces trained immunity, we will be able to design better vaccines for the elderly. The Key objectives of the project are: Key objective 1: To describe the innate immune cell (sub)populations, and their heterogeneity at single-cell level, responsible for mediating trained immunity in the young and elderly adults. Key objective 2: To identify the complex genetic, epigenetic, microbiome, and metabolic programs that represent the molecular and biochemical substrates of trained immunity in the myeloid cells of the elderly individuals. Key objective 3: To use systems biology to map the heterogeneity of trained immunity response determined by host (epi)genome, microbiome, and environmental factors in the elderly. Expected results: We will understand the main cellular and molecular mechanisms for the induction of trained immunity responses in vivo and the specificities of the response in the elderly. These findings will enable the design of innovative approaches to improve vaccination strategies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRAIN-OLD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRAIN-OLD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

AllergenDetect (2019)

Comprehensive allergen detection using synthetic DNA libraries

Read More  

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More  

TroyCAN (2020)

Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma

Read More